Return to Search
EN
Bone marrow transplantation, while a life-saving procedure, carries several potential complications. These include:
* Graft-versus-host disease (GVHD), which is specific to allogeneic transplants.
* Graft failure.
* Organ damage, potentially affecting organs such as the liver, kidneys, or lungs.
* Various infections.
* Secondary complications like cataracts, infertility, or new cancers.
Graft-versus-Host Disease (GVHD):
GVHD is a significant and potentially severe complication unique to allogeneic hematopoietic stem cell transplantation (HSCT). It occurs when the donor's immune cells (specifically T-lymphocytes) recognize the recipient's cells as foreign and initiate an immune attack, leading to widespread inflammation and organ dysfunction. GVHD is a major cause of morbidity and mortality following allogeneic HSCT.
GVHD can manifest either acutely, typically within the first few months post-transplant, or chronically, potentially appearing more than a year after the procedure.
* Acute GVHD commonly affects the skin (presenting as rashes), the gastrointestinal tract (causing symptoms like diarrhea, nausea, and vomiting), and the liver (leading to jaundice).
* Chronic GVHD can impact multiple organ systems, often causing more severe and long-lasting damage. Its diverse symptoms may include joint or muscle pain, shortness of breath, persistent cough, changes in vision, skin alterations (such as scarring, hardening, or rashes), jaundice (yellowing of the skin or whites of the eyes), mouth sores, diarrhea, nausea, and vomiting.
What are the possible complications associated with bone marrow transplantation?
* Graft-versus-host disease (GVHD), which is specific to allogeneic transplants.
* Graft failure.
* Organ damage, potentially affecting organs such as the liver, kidneys, or lungs.
* Various infections.
* Secondary complications like cataracts, infertility, or new cancers.
Graft-versus-Host Disease (GVHD):
GVHD is a significant and potentially severe complication unique to allogeneic hematopoietic stem cell transplantation (HSCT). It occurs when the donor's immune cells (specifically T-lymphocytes) recognize the recipient's cells as foreign and initiate an immune attack, leading to widespread inflammation and organ dysfunction. GVHD is a major cause of morbidity and mortality following allogeneic HSCT.
GVHD can manifest either acutely, typically within the first few months post-transplant, or chronically, potentially appearing more than a year after the procedure.
* Acute GVHD commonly affects the skin (presenting as rashes), the gastrointestinal tract (causing symptoms like diarrhea, nausea, and vomiting), and the liver (leading to jaundice).
* Chronic GVHD can impact multiple organ systems, often causing more severe and long-lasting damage. Its diverse symptoms may include joint or muscle pain, shortness of breath, persistent cough, changes in vision, skin alterations (such as scarring, hardening, or rashes), jaundice (yellowing of the skin or whites of the eyes), mouth sores, diarrhea, nausea, and vomiting.